MindwaysCT received 510(k) clearance from the U.S. Food and Drug Administration to market its quantitative computed tomography calibration technology for CT-based bone mineral density measurement.
MindwaysCT's latest QCT software innovation makes it possible to assess bone mineral density using QCT without the need to scan a calibration phantom together with the patient. The new technology can also offer retrospective analysis of previously acquired images.
More articles on devices:
aap Implantate receives patent for LOQTEQNuVasive COO sells 2.5k shares in $87k transaction
$0.9B by 2019: 3D printing in medical applications market analysis